Results 181 to 190 of about 7,961 (203)
Some of the next articles are maybe not open access.
Papilledema in idiopathic inflammatory polyradiculoneuropathy
The Italian Journal of Neurological Sciences, 1986Papilledema is a rare finding in idiopathic inflammatory polyradiculoneuropathy. A case in which the papilledema arose at the beginning of the disease and had a favorable course is reported and the principal hypotheses regarding its pathogenesis are discussed.
G, Sozzi, P, Marotta
openaire +2 more sources
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurology Clinical Practice, 2022The purpose of this review is to give an update on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).There are several recent developments in CIDP, the major one being the 2021 second revision of the European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating ...
openaire +2 more sources
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Archives of Neurology, 2004For much of the 20th century, our understanding of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was limited because the condition went by several different names; clinical and histopathologic descriptions were often combined with those of similar neuropathic disorders including Guillain-Barré syndrome, the hereditary hypertrophic ...
openaire +2 more sources
Polyradiculoneuropathy in dourine-affected horses
Neuromuscular Disorders, 2019Dourine is an equine protozoan disease caused by Trypanosoma equiperdum. Dourine-afflicted animals die after developing neurological clinical signs, such as unilateral paresis. The disease has been a problem for many years; however, the pathogenesis regarding the neurological clinical signs of dourine has been unclear.
Bayasgalan, Mungun-Ochir +13 more
openaire +2 more sources
Chronic inflammatory demyelinating polyradiculoneuropathy
Clinical Neurology and Neurosurgery, 1991During recent years chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) has been characterized on the basis of clinical and laboratory findings. Immune modifying treatment with glucocorticoids, plasma exchange and infusion of immune globulins has had a therapeutic effect in controlled studies.
F. Barbieri +4 more
openaire +3 more sources
Progressive Polyradiculoneuropathy: Treatment with Azathioprine
Australian and New Zealand Journal of Medicine, 1979Summary: A case is presented of a 64‐year‐old male with chronic inflammatory polyradiculoneuropathy (CIP) relentlessly progressing (despite steroids) to virtually complete quadriplegia over seven months. Once commenced on Azathioprine he dramatically improved over a six week period.The truly progressive form of CIP is rare.
openaire +2 more sources
Chronic inflammatory polyradiculoneuropathy.
Mayo Clinic proceedings, 1976The diagnostic criteria, natural history, nerve conduction characteristics, pathology, laboratory features, and efficacy of corticosteroid treatment have been evaluated personally in 53 patients with chronic inflammatory polyradiculoneuropathy (CIP) who were followed up for an average of about 7.5 years.
P J, Dyck +5 more
openaire +1 more source
Recurrent polyradiculoneuropathy with the 17p11.2 deletion
Muscle & Nerve, 1997Hereditary neuropathy with liability to pressure palsies (HNPP) classically occurs as recurrent focal neuropathy. We report the first known instance of HNPP manifesting, over a 15-year period, as a recurrent sensorimotor polyneuropathy and confirmed by the presence of the PMP-22 gene deletion.
N, Le Forestier +7 more
openaire +2 more sources
[Acute autoimmune polyradiculoneuropathies].
Revista de neurologia, 2002Landry Guillain Barr Sthrol Syndrome (LGBS) is an acute autoimmune monophasic and selflimiting polyradiculoneuropathy affecting patients aged 19 to 59 years (1.7/100,000/year) more than below 18 year of age (0.8/100,000/year). Diagnostic criteria require: I.
O, Papazian, I, Alfonso
openaire +1 more source
Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy
New England Journal of Medicine, 2016This letter reports two cases of severe demyelinating polyradiculoneuropathy after treatment with pembrolizumab, a humanized antibody against programmed cell death 1 receptor, for advanced melanoma.
Marie-Florence de Maleissye +2 more
openaire +1 more source

